Matinas BioPharma Holdings Inc./$MTNB
1D1W1MYTD1Y5YMAX
Capital at risk
About Matinas BioPharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
- Ticker
- $MTNB
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 2
- Headquarters
- Bedminster, United States
- Website
- www.matinasbiopharma.com
MTNB Metrics
BasicAdvanced
$2.4M
-
-$1.19
1.75
-
Price and volume
Market cap
$2.4M
Beta
1.75
52-week high
$2.14
52-week low
$0.15
Average daily volume
1.2M
Financial strength
Current ratio
0.847
Quick ratio
0.564
Long term debt to equity
0.003
Total debt to equity
0.003
Interest coverage (TTM)
-6,667.00%
Profitability
EBITDA (TTM)
-6.662
Management effectiveness
Return on assets (TTM)
-56.17%
Return on equity (TTM)
-141.23%
Valuation
Price to book
0.57
Price to tangible book (TTM)
0.57
Price to free cash flow (TTM)
-0.153
Free cash flow yield (TTM)
-652.57%
Free cash flow per share (TTM)
-1.047
Growth
Earnings per share change (TTM)
-69.16%
3-year earnings per share growth (CAGR)
-36.98%
10-year earnings per share growth (CAGR)
-16.24%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.